PRL-295

Overview

PRL-295 is an orally active inhibitor targeting Keap1-Nrf2 interaction. PRL-295 increases the thermal stability of Keap1 and disrupts its interaction with Nrf2, thereby activating the Nrf2-dependent transcriptional target NAD(P)H:quinone oxidoreductase 1 (NQO1) . PRL-295 protects against Acetaminophen ( HY-66005 )-induced liver injury in mice.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Quinone Reductase | Products > Signaling Pathways > Keap1-Nrf2 | Products > Signaling Pathways > Aminotransferases (Transaminases)

Product Information

• Catalog No.: HY-171035
• CAS No.: 2377770-85-7
• Molecular Formula: C27H24F3N3O8S2
• Molecular Weight: 639.62
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source